Canine Polycythemia: Diagnosis and Management

Polycythemia in dogs is an abnormal increase in circulating red blood cell mass, classified as relative or absolute, with absolute polycythemia further divided into primary (polycythemia vera) and secondary forms. This article provides veterinarians with a systematic approach to differentiate these conditions and implement appropriate management strategies, including phlebotomy and hydroxyurea therapy, while addressing underlying causes.

At a Glance

Classification of Polycythemia

Relative Polycythemia

Relative polycythemia results from decreased plasma volume instead of increased red blood cell mass. Common causes include dehydration from vomiting, diarrhea, or reduced water intake. Splenic contraction can transiently elevate PCV but does not represent true polycythemia. The Merck Veterinary Manual provides general guidance on hemoconcentration states in dogs (Merck Veterinary Manual, https://www.merckvetmanual.com/). Diagnosis relies on history, physical examination findings of dehydration, and response to fluid therapy. PCV normalizes after rehydration in relative polycythemia.

Absolute Polycythemia

Absolute polycythemia indicates a true increase in red blood cell mass. This is further classified into primary and secondary forms based on serum erythropoietin concentration and the presence of underlying disease.

Primary Polycythemia (Polycythemia Vera)

Primary polycythemia, also called polycythemia vera, is a myeloproliferative disorder characterized by autonomous proliferation of erythroid precursors in the bone marrow. Serum erythropoietin levels are low or inappropriately normal. This condition has been documented in dogs, with early reports describing the clinical and hematologic features (Polycythemia vera in a dog, Journal of the American Veterinary Medical Association, 1969, https://pubmed.ncbi.nlm.nih.gov/5812582, Polycythemia vera in dogs, Journal of the American Veterinary Medical Association, 1974, https://pubmed.ncbi.nlm.nih.gov/4857967). Affected dogs may present with neurologic signs, ocular abnormalities, or nonspecific clinical signs. One case report described a dog with polycythemia vera presenting with uveitis (Polycythemia vera in a dog presenting with uveitis, Journal of the American Animal Hospital Association, 2003, https://pubmed.ncbi.nlm.nih.gov/12873025). Additional case reports have described the clinical presentation and management of polycythemia vera in dogs (Polycythaemia vera in a dog, The Veterinary record, 1987, https://pubmed.ncbi.nlm.nih.gov/3603998, Polycythaemia vera in a dog, Journal of the South African Veterinary Association, 1990, https://pubmed.ncbi.nlm.nih.gov/9022852, Diagnosis and Treatment of Primary Erythrocytosis in a Dog: A Case Report, Topics in companion animal medicine, 2015, https://pubmed.ncbi.nlm.nih.gov/26359727, A case of primary polycythaemia in a dog, Point Veterinaire, 2009, https://api.elsevier.com/content/abstract/scopus_id/75449116162).

Secondary Polycythemia

Secondary polycythemia results from increased erythropoietin production. Appropriate secondary polycythemia occurs as a physiologic response to chronic tissue hypoxia, such as in congenital heart disease, chronic pulmonary disease, or high-altitude living. Inappropriate secondary polycythemia arises from pathologic erythropoietin secretion by renal neoplasia, renal cysts, or other tumors. Endocrine disorders such as hyperadrenocorticism may also contribute. The American College of Veterinary Internal Medicine provides resources on diagnostic approaches for these conditions (ACVIM, https://www.acvim.org/).

Diagnostic Workup

Initial Assessment and History

Begin with a thorough history including signalment, duration of clinical signs, and any known underlying conditions. Document any episodes of weakness, collapse, seizures, or visual deficits. Inquire about access to toxins, travel history, and altitude exposure. The American Animal Hospital Association offers practice guidelines for diagnostic workups in companion animals (AAHA, https://www.aaha.org/resources).

Physical Examination

Perform a complete physical examination with attention to mucous membrane color (plethora), injection of conjunctival vessels, and retinal examination. Neurologic assessment is critical as hyperviscosity can cause cerebral signs. Cardiac and respiratory examinations help identify underlying causes of hypoxia. Palpate the abdomen for renal masses or organomegaly.

Laboratory Evaluation

Complete Blood Count

PCV is the primary screening test. In polycythemia vera, PCV typically exceeds 55-60% in dogs, though thresholds vary by breed and laboratory. Evaluate red blood cell indices, white blood cell count, and platelet count. Some dogs with polycythemia vera may have concurrent thrombocytosis or leukocytosis.

Serum Erythropoietin Concentration

Serum erythropoietin measurement is the key test to differentiate primary from secondary polycythemia. Low or inappropriately normal erythropoietin in the face of elevated PCV suggests primary polycythemia. Elevated erythropoietin indicates secondary polycythemia. Interpret results with caution as erythropoietin assays have variability.

Blood Gas Analysis

Arterial blood gas measurement assesses oxygenation. Hypoxemia (low PaO2) supports appropriate secondary polycythemia. Normal PaO2 suggests primary polycythemia or inappropriate secondary polycythemia.

Serum Biochemistry Profile

Evaluate renal function, liver enzymes, electrolytes, and total protein. Azotemia may indicate renal disease as a cause of inappropriate erythropoietin production. Hyperproteinemia can occur with dehydration.

Urinalysis

Assess urine specific gravity, protein, and sediment. Proteinuria or hematuria may suggest renal pathology.

Imaging Studies

Thoracic Radiography

Evaluate for pulmonary disease, cardiac enlargement, or neoplasia. Chronic hypoxic lung disease or congenital heart defects may be identified.

Abdominal Ultrasound

Examine kidneys for masses, cysts, or structural abnormalities. Renal neoplasia is a recognized cause of inappropriate erythropoietin secretion. Also assess liver and spleen for evidence of myeloproliferative disease.

Echocardiography

If cardiac disease is suspected, echocardiography helps identify congenital shunts or acquired heart disease causing hypoxia.

Bone Marrow Evaluation

Bone marrow aspiration and core biopsy are indicated when primary polycythemia is suspected. Findings typically show erythroid hyperplasia with normal maturation. In polycythemia vera, all cell lines may be increased. Bone marrow evaluation also helps exclude other myeloproliferative disorders.

Diagnostic Decision Pathway

Treatment Options

Phlebotomy

Phlebotomy is the initial treatment for acute management of hyperviscosity and for long-term control in primary polycythemia. The goal is to reduce PCV to a target range (typically 45-50%) and alleviate clinical signs.

Procedure

Place an intravenous catheter in a jugular or large peripheral vein. Remove 10-20 mL/kg of whole blood, depending on the dog's size and PCV. Monitor vital signs during the procedure. Replace removed volume with an equal volume of isotonic crystalloid fluids to maintain hemodynamic stability. Repeat phlebotomy every 24-72 hours until PCV reaches target.

Monitoring

Measure PCV before each phlebotomy session. Record volume removed, PCV before and after, and clinical response. Frequency of phlebotomy depends on the rate of PCV increase. Some dogs require weekly phlebotomy initially, then less frequently as hydroxyurea takes effect.

Limitations

Phlebotomy alone may not adequately control PCV in all dogs. Repeated phlebotomy can cause iron deficiency, which may limit erythroid production but also leads to microcytosis and hypochromia. Iron supplementation is not recommended in polycythemia vera as it may stimulate erythropoiesis.

Hydroxyurea

Hydroxyurea is a chemotherapeutic agent that inhibits ribonucleotide reductase, suppressing bone marrow production of red blood cells. It is the mainstay of long-term medical management for primary polycythemia in dogs.

Indications

Hydroxyurea is indicated for dogs with primary polycythemia that require ongoing control beyond phlebotomy. It is also used when phlebotomy alone is insufficient or impractical.

Administration

Hydroxyurea is administered orally. Dosing must be individualized based on PCV response and tolerance. The Merck Veterinary Manual provides general information on chemotherapeutic agents in veterinary medicine (Merck Veterinary Manual, https://www.merckvetmanual.com/). Treatment typically begins at a low dose with gradual adjustment.

Monitoring

Monitor PCV weekly during induction, then monthly once stable. Perform complete blood counts to assess for myelosuppression, particularly thrombocytopenia and leukopenia. Adjust dose based on PCV and blood cell counts.

Adverse Effects

Myelosuppression is the primary dose-limiting toxicity. Gastrointestinal signs such as vomiting or diarrhea may occur. Long-term use requires periodic monitoring of liver and kidney function.

Addressing Underlying Causes

Secondary Polycythemia

Treatment of secondary polycythemia focuses on the underlying condition. For appropriate secondary polycythemia due to hypoxia, address the cardiac or pulmonary disease. Surgical correction of congenital heart defects may resolve polycythemia. For inappropriate secondary polycythemia due to renal neoplasia, nephrectomy or tumor removal may be curative. Renal cysts causing erythropoietin production may require drainage or surgical management.

Relative Polycythemia

Correct dehydration with appropriate fluid therapy. Identify and treat the underlying cause of fluid loss.

Practical Implementation Steps

Step 1: Confirm Polycythemia

Measure PCV on at least two occasions to confirm persistent elevation. Exclude relative polycythemia by assessing hydration status and response to fluid therapy.

Step 2: Classify Polycythemia

Obtain serum erythropoietin concentration, arterial blood gas, and imaging studies. Low erythropoietin with normal PaO2 suggests primary polycythemia. High erythropoietin with low PaO2 suggests appropriate secondary polycythemia. High erythropoietin with normal PaO2 suggests inappropriate secondary polycythemia.

Step 3: Initiate Phlebotomy

If PCV exceeds 60% or the dog shows clinical signs of hyperviscosity, perform phlebotomy immediately. Target PCV of 45-50%. Repeat as needed.

Step 4: Start Hydroxyurea

For confirmed primary polycythemia, begin hydroxyurea therapy. Adjust dose based on PCV response and blood cell counts.

Step 5: Treat Underlying Cause

For secondary polycythemia, address the identified underlying condition. Refer to appropriate specialists for cardiac, pulmonary, renal, or endocrine management.

Step 6: Monitor Long-Term

Schedule regular rechecks with PCV, complete blood count, and clinical assessment. Adjust treatment as needed.

Records and Measurements

Maintain detailed records for each dog with polycythemia:

• Date and time of each PCV measurement
• Volume of blood removed during phlebotomy
• PCV before and after phlebotomy
• Hydroxyurea dose and frequency
• Complete blood count results including white blood cell and platelet counts
• Serum erythropoietin levels
• Blood gas results
• Imaging findings
• Clinical signs and response to treatment
• Adverse effects or complications

Use a standardized form to track these parameters over time. This documentation supports treatment decisions and helps identify trends.

Common Failure Patterns

Failure to Differentiate Primary from Secondary

Misclassification leads to inappropriate treatment. Always measure serum erythropoietin and perform blood gas analysis before committing to long-term therapy. Imaging is essential to exclude renal or other causes.

Inadequate Phlebotomy

Removing insufficient blood volume or not replacing volume can lead to persistent hyperviscosity or hypovolemia. Follow protocol for volume removal and fluid replacement.

Hydroxyurea Overdose or Underdose

Starting at too high a dose causes myelosuppression. Starting too low delays PCV control. Monitor blood counts closely and adjust gradually.

Ignoring Underlying Disease

Treating secondary polycythemia with hydroxyurea alone misses the opportunity to address the root cause. Always investigate for cardiac, pulmonary, renal, or endocrine disease.

Poor Owner Compliance

Long-term management requires owner commitment to medication administration, regular rechecks, and phlebotomy visits. Educate owners about the chronic nature of the disease and the importance of monitoring.

Welfare and Safety Context

Polycythemia causes significant morbidity due to hyperviscosity syndrome. Clinical signs include lethargy, weakness, ataxia, seizures, blindness, and bleeding tendencies. Untreated polycythemia can lead to thromboembolic events, stroke, or death. The World Organisation for Animal Health emphasizes the importance of timely diagnosis and treatment to maintain animal health and welfare (World Organisation for Animal Health, Animal Health and Welfare, https://www.woah.org/en/what-we-do/animal-health-and-welfare).

Phlebotomy is generally safe when performed correctly. Risks include hypovolemia, infection at venipuncture site, and hematoma formation. Hydroxyurea is a chemotherapeutic agent, handle with gloves and avoid exposure to pregnant women. Owners should be counseled on safe handling and disposal of medication.

Limitations and Professional Escalation Criteria

Limitations of Diagnostic Tests

Serum erythropoietin assays may have variable sensitivity and specificity. Results should be interpreted in conjunction with clinical findings and other tests. Bone marrow evaluation requires specialized expertise and may not be available in all practices.

When to Refer

Refer to a veterinary internal medicine specialist in the following situations:

• Difficulty differentiating primary from secondary polycythemia
• Poor response to phlebotomy or hydroxyurea
• Suspected renal neoplasia requiring surgical management
• Complex cardiac or pulmonary disease
• Recurrent thromboembolic events
• Severe myelosuppression from hydroxyurea

Emergency Situations

Seek immediate veterinary emergency care for:

• Acute neurologic signs (seizures, collapse, stupor)
• Sudden blindness
• Evidence of thromboembolism (acute pain, limb ischemia, respiratory distress)
• PCV above 70% with clinical signs

Practical Decision Framework for Phlebotomy and Hydroxyurea Dose Titration in Canine Polycythemia

Managing polycythemia in dogs requires a structured approach to phlebotomy scheduling and hydroxyurea dose adjustment that accounts for individual patient variability. The following framework provides veterinarians with a step-by-step decision process based on serial PCV measurements, clinical response, and hematologic monitoring. This system is designed to reduce common errors in treatment intensity and timing while maintaining patient safety.

Phlebotomy Decision Algorithm

The decision to perform phlebotomy and the volume of blood to remove depend on the presenting PCV, clinical signs of hyperviscosity, and the dog's cardiovascular status. Begin by confirming the PCV with a spun hematocrit or automated analyzer reading. If the PCV exceeds 60% or the dog shows neurologic signs, ocular abnormalities, or evidence of thromboembolism, proceed with phlebotomy immediately. For dogs with PCV between 55% and 60% that are asymptomatic, consider a more conservative approach with close monitoring and repeat PCV measurement within 24 to 48 hours.

Volume Calculation

Remove 10 to 20 mL of whole blood per kilogram of body weight per session. Use the lower end of this range for small dogs, geriatric patients, or those with compromised cardiac function. Use the higher end for large breed dogs with PCV above 65% and no contraindications. Calculate the exact volume based on the dog's current PCV and target PCV of 45% to 50%. A simplified formula is: volume to remove (mL) equals body weight (kg) multiplied by 15 mL, adjusted based on clinical judgment. Replace the removed volume with an equal volume of isotonic crystalloid fluids administered intravenously during or immediately after phlebotomy.

Session Frequency

Perform phlebotomy every 24 to 72 hours until the PCV reaches the target range. After each session, measure PCV before the next phlebotomy to assess the rate of PCV rebound. Record the PCV trend over consecutive sessions. If the PCV decreases by less than 5% after a session, consider increasing the volume removed by 2 to 5 mL/kg in the next session, provided the dog tolerated the previous procedure well. If the PCV drops below 40% after phlebotomy, reduce the volume removed in subsequent sessions and extend the interval between sessions.

Hydroxyurea Dose Titration Protocol

Hydroxyurea is the primary long-term medical therapy for primary polycythemia in dogs. The goal is to maintain PCV between 45% and 50% with the lowest effective dose that avoids myelosuppression. Begin hydroxyurea after the initial phlebotomy sessions have reduced PCV to the target range. Starting hydroxyurea while PCV is still above 60% delays the onset of therapeutic effect and increases the risk of ongoing hyperviscosity.

Initial Dose Selection

Start hydroxyurea at a low dose to minimize the risk of myelosuppression. A typical starting dose is 15 to 20 mg per kilogram orally once daily for 7 to 14 days. After this induction period, reduce the frequency to every other day or three times per week for maintenance. The Merck Veterinary Manual provides general guidance on chemotherapeutic dosing in dogs (Merck Veterinary Manual, https://www.merckvetmanual.com/). Individualize the starting dose based on the dog's body weight, baseline white blood cell count, and platelet count. Dogs with preexisting thrombocytopenia or leukopenia should receive the lower end of the dose range.

Dose Adjustment Based on PCV Response

Monitor PCV weekly during the first month of hydroxyurea therapy. If the PCV remains above 55% after two weeks of treatment, increase the dose by 5 to 10 mg per kilogram per day, not exceeding 30 mg per kilogram per day. If the PCV drops below 40%, reduce the dose by 5 to 10 mg per kilogram per day or extend the dosing interval to every third day. Once the PCV stabilizes in the target range for four consecutive weeks, reduce monitoring frequency to monthly.

Dose Adjustment Based on Myelosuppression

Perform a complete blood count before each dose adjustment and at least monthly during maintenance therapy. Hydroxyurea causes dose-dependent myelosuppression, primarily affecting platelets and white blood cells. If the platelet count falls below 150,000 per microliter or the white blood cell count falls below 4,000 per microliter, hold the hydroxyurea dose until counts recover. Resume at a dose reduced by 25% to 50% of the previous dose. If severe myelosuppression occurs with platelet count below 100,000 per microliter or white blood cell count below 2,500 per microliter, discontinue hydroxyurea and consider alternative therapy or referral to a veterinary internal medicine specialist.

Record System for Treatment Monitoring

Maintain a standardized treatment log for each dog with polycythemia. This record supports clinical decisions and helps identify trends that require dose adjustment. Include the following fields for each visit:

• Date and time of visit
• PCV before phlebotomy or dose adjustment
• Volume of blood removed during phlebotomy (mL)
• PCV after phlebotomy
• Hydroxyurea dose (mg per kg) and frequency
• Complete blood count results: white blood cell count, platelet count, red blood cell indices
• Clinical signs present at visit
• Adverse effects observed or reported by owner
• Next scheduled visit date

Use a graph or spreadsheet to plot PCV over time. This visual representation helps identify patterns such as rapid PCV rebound, delayed response to hydroxyurea, or gradual drift out of target range. Record any changes in the dog's clinical status, including neurologic signs, ocular abnormalities, or evidence of thromboembolism.

Troubleshooting Common Treatment Challenges

Persistent PCV Above Target Despite Phlebotomy and Hydroxyurea

If the PCV remains above 55% after four weeks of hydroxyurea therapy at the maximum tolerated dose, reassess the diagnosis. Confirm that the dog has primary polycythemia and not secondary polycythemia from an unrecognized underlying cause. Repeat serum erythropoietin measurement and arterial blood gas analysis. Perform abdominal ultrasound to evaluate for renal neoplasia or cysts. Consider thoracic radiography or echocardiography to identify cardiac or pulmonary disease. If the diagnosis of primary polycythemia is confirmed, increase phlebotomy frequency to every 7 to 10 days and consider adding a second agent such as chlorambucil or busulfan, though these drugs require specialist consultation.

Rapid PCV Rebound After Phlebotomy

Some dogs with primary polycythemia show rapid PCV rebound within 48 to 72 hours after phlebotomy. This pattern suggests highly active erythroid proliferation. Increase the volume of blood removed in subsequent phlebotomy sessions by 2 to 5 mL per kilogram, provided the dog tolerates the procedure. Consider initiating hydroxyurea at a higher starting dose, such as 20 mg per kilogram per day, and monitor PCV more frequently, every 3 to 4 days, until the rebound slows.

Hydroxyurea-Induced Myelosuppression

Myelosuppression is the most common dose-limiting toxicity of hydroxyurea. If the platelet count drops below 150,000 per microliter or the white blood cell count drops below 4,000 per microliter, hold the drug for 7 to 14 days. Repeat the complete blood count after the drug holiday. Once counts recover, resume hydroxyurea at 50% to 75% of the previous dose. If myelosuppression recurs at the reduced dose, consider switching to an every-third-day dosing schedule or using a lower dose combined with more frequent phlebotomy. Severe or persistent myelosuppression warrants referral to a veterinary internal medicine specialist.

Poor Owner Compliance with Medication and Monitoring

Long-term management of polycythemia requires owner commitment to daily medication administration, regular veterinary visits, and phlebotomy sessions. Educate owners about the chronic nature of the disease and the consequences of treatment interruption. Provide a written treatment schedule and a log for recording medication administration and any observed clinical signs. Schedule recheck appointments before the owner leaves the clinic to reduce missed visits. If compliance remains poor, consider using a longer-acting formulation or simplifying the dosing schedule to every other day.

Comparison of Phlebotomy-Only Versus Combined Phlebotomy and Hydroxyurea

Practical Implementation Steps for Dose Titration

Step 1: Establish Baseline

Measure PCV, complete blood count, serum erythropoietin, and arterial blood gas. Perform imaging studies to classify polycythemia. Record baseline white blood cell count and platelet count.

Step 2: Perform Initial Phlebotomy

If PCV exceeds 60% or clinical signs are present, perform phlebotomy at 15 mL per kilogram. Replace volume with isotonic crystalloid fluids. Measure PCV after the procedure.

Step 3: Repeat Phlebotomy as Needed

Monitor PCV every 24 to 72 hours. Repeat phlebotomy until PCV reaches 45% to 50%. Record the number of sessions required and the total volume removed.

Step 4: Initiate Hydroxyurea

Once PCV is in target range, start hydroxyurea at 15 to 20 mg per kilogram once daily for 7 to 14 days. Reduce to every-other-day dosing for maintenance.

Step 5: Monitor and Adjust

Check PCV and complete blood count weekly for the first month. Adjust hydroxyurea dose based on PCV response and blood cell counts. Once stable, monitor monthly.

Step 6: Long-Term Maintenance

Continue monthly monitoring. Adjust phlebotomy frequency and hydroxyurea dose as needed to maintain PCV between 45% and 50%. Record all treatments and results in the standardized log.

Common Failure Patterns in Dose Titration

Starting Hydroxyurea Too Early

Initiating hydroxyurea before reducing PCV with phlebotomy delays the therapeutic effect and prolongs the period of hyperviscosity. Always perform initial phlebotomy to bring PCV into target range before starting hydroxyurea.

Insufficient Dose Adjustment

Failing to increase the hydroxyurea dose when PCV remains above target leads to persistent hyperviscosity. Increase the dose by 5 to 10 mg per kilogram per day if PCV does not decrease within two weeks.

Overly Aggressive Dose Escalation

Increasing the hydroxyurea dose too rapidly or to too high a level causes myelosuppression. Never exceed 30 mg per kilogram per day without specialist consultation. Monitor blood counts before each dose adjustment.

Ignoring Clinical Signs

Relying solely on PCV without considering clinical signs can lead to undertreatment or overtreatment. A dog with PCV of 52% but showing neurologic signs may require more aggressive therapy than a dog with PCV of 58% that is asymptomatic.

Discontinuing Phlebotomy Too Soon

Some dogs require ongoing phlebotomy even after hydroxyurea therapy is established. Continue phlebotomy until PCV stabilizes in target range for at least four consecutive weeks without phlebotomy.

Welfare and Safety Context

Proper dose titration of phlebotomy and hydroxyurea directly impacts patient welfare. Overly aggressive phlebotomy causes hypovolemia, weakness, and collapse. Inadequate phlebotomy leaves the dog at risk for thromboembolism, stroke, and blindness. Hydroxyurea overdose causes severe myelosuppression leading to infection risk and bleeding tendencies. Underdosing delays PCV control and prolongs hyperviscosity. The World Organisation for Animal Health emphasizes the importance of evidence-based treatment protocols to maintain animal health and welfare (World Organisation for Animal Health, Animal Health and Welfare, https://www.woah.org/en/what-we-do/animal-health-and-welfare).

Handle hydroxyurea with gloves and avoid exposure to pregnant women. Advise owners to wear gloves when administering the medication and to wash hands thoroughly after handling. Store hydroxyurea in a childproof container away from pets and children.

Limitations and Professional Escalation Criteria

The dose titration framework is based on published case reports and clinical experience. Individual dogs may respond differently to phlebotomy and hydroxyurea. The framework does not replace clinical judgment. Refer to a veterinary internal medicine specialist in the following situations:

• PCV remains above 55% after four weeks of hydroxyurea at 30 mg per kilogram per day
• Severe myelosuppression occurs with platelet count below 100,000 per microliter or white blood cell count below 2,500 per microliter
• The dog develops recurrent thromboembolic events despite adequate PCV control
• The dog shows progressive neurologic signs or blindness
• The diagnosis between primary and secondary polycythemia remains unclear after initial workup
• The owner cannot manage the treatment regimen and requires specialist support

Emergency referral is indicated for acute neurologic signs, sudden blindness, or evidence of thromboembolism such as acute pain, limb ischemia, or respiratory distress.

Practical Decision Framework for Phlebotomy and Hydroxyurea Dose Titration in Canine Polycythemia

Managing polycythemia in dogs requires a structured approach to phlebotomy scheduling and hydroxyurea dose adjustment that accounts for individual patient variability. The following framework provides veterinarians with a step-by-step decision process based on serial PCV measurements, clinical response, and hematologic monitoring. This system is designed to reduce common errors in treatment intensity and timing while maintaining patient safety.

Phlebotomy Decision Algorithm

The decision to perform phlebotomy and the volume of blood to remove depend on the presenting PCV, clinical signs of hyperviscosity, and the dog's cardiovascular status. Begin by confirming the PCV with a spun hematocrit or automated analyzer reading. If the PCV exceeds 60% or the dog shows neurologic signs, ocular abnormalities, or evidence of thromboembolism, proceed with phlebotomy immediately. For dogs with PCV between 55% and 60% that are asymptomatic, consider a more conservative approach with close monitoring and repeat PCV measurement within 24 to 48 hours.

Volume Calculation

Remove 10 to 20 mL of whole blood per kilogram of body weight per session. Use the lower end of this range for small dogs, geriatric patients, or those with compromised cardiac function. Use the higher end for large breed dogs with PCV above 65% and no contraindications. Calculate the exact volume based on the dog's current PCV and target PCV of 45% to 50%. A simplified formula is: volume to remove (mL) equals body weight (kg) multiplied by 15 mL, adjusted based on clinical judgment. Replace the removed volume with an equal volume of isotonic crystalloid fluids administered intravenously during or immediately after phlebotomy.

Session Frequency

Perform phlebotomy every 24 to 72 hours until the PCV reaches the target range. After each session, measure PCV before the next phlebotomy to assess the rate of PCV rebound. Record the PCV trend over consecutive sessions. If the PCV decreases by less than 5% after a session, consider increasing the volume removed by 2 to 5 mL/kg in the next session, provided the dog tolerated the previous procedure well. If the PCV drops below 40% after phlebotomy, reduce the volume removed in subsequent sessions and extend the interval between sessions.

Hydroxyurea Dose Titration Protocol

Hydroxyurea is the primary long-term medical therapy for primary polycythemia in dogs. The goal is to maintain PCV between 45% and 50% with the lowest effective dose that avoids myelosuppression. Begin hydroxyurea after the initial phlebotomy sessions have reduced PCV to the target range. Starting hydroxyurea while PCV is still above 60% delays the onset of therapeutic effect and increases the risk of ongoing hyperviscosity.

Initial Dose Selection

Start hydroxyurea at a low dose to minimize the risk of myelosuppression. A typical starting dose is 15 to 20 mg per kilogram orally once daily for 7 to 14 days. After this induction period, reduce the frequency to every other day or three times per week for maintenance. The Merck Veterinary Manual provides general guidance on chemotherapeutic dosing in dogs (Merck Veterinary Manual, https://www.merckvetmanual.com/). Individualize the starting dose based on the dog's body weight, baseline white blood cell count, and platelet count. Dogs with preexisting thrombocytopenia or leukopenia should receive the lower end of the dose range.

Dose Adjustment Based on PCV Response

Monitor PCV weekly during the first month of hydroxyurea therapy. If the PCV remains above 55% after two weeks of treatment, increase the dose by 5 to 10 mg per kilogram per day, not exceeding 30 mg per kilogram per day. If the PCV drops below 40%, reduce the dose by 5 to 10 mg per kilogram per day or extend the dosing interval to every third day. Once the PCV stabilizes in the target range for four consecutive weeks, reduce monitoring frequency to monthly.

Dose Adjustment Based on Myelosuppression

Perform a complete blood count before each dose adjustment and at least monthly during maintenance therapy. Hydroxyurea causes dose-dependent myelosuppression, primarily affecting platelets and white blood cells. If the platelet count falls below 150,000 per microliter or the white blood cell count falls below 4,000 per microliter, hold the hydroxyurea dose until counts recover. Resume at a dose reduced by 25% to 50% of the previous dose. If severe myelosuppression occurs with platelet count below 100,000 per microliter or white blood cell count below 2,500 per microliter, discontinue hydroxyurea and consider alternative therapy or referral to a veterinary internal medicine specialist.

Record System for Treatment Monitoring

Maintain a standardized treatment log for each dog with polycythemia. This record supports clinical decisions and helps identify trends that require dose adjustment. Include the following fields for each visit:

• Date and time of visit
• PCV before phlebotomy or dose adjustment
• Volume of blood removed during phlebotomy (mL)
• PCV after phlebotomy
• Hydroxyurea dose (mg per kg) and frequency
• Complete blood count results: white blood cell count, platelet count, red blood cell indices
• Clinical signs present at visit
• Adverse effects observed or reported by owner
• Next scheduled visit date

Use a graph or spreadsheet to plot PCV over time. This visual representation helps identify patterns such as rapid PCV rebound, delayed response to hydroxyurea, or gradual drift out of target range. Record any changes in the dog's clinical status, including neurologic signs, ocular abnormalities, or evidence of thromboembolism.

Troubleshooting Common Treatment Challenges

Persistent PCV Above Target Despite Phlebotomy and Hydroxyurea

If the PCV remains above 55% after four weeks of hydroxyurea therapy at the maximum tolerated dose, reassess the diagnosis. Confirm that the dog has primary polycythemia and not secondary polycythemia from an unrecognized underlying cause. Repeat serum erythropoietin measurement and arterial blood gas analysis. Perform abdominal ultrasound to evaluate for renal neoplasia or cysts. Consider thoracic radiography or echocardiography to identify cardiac or pulmonary disease. If the diagnosis of primary polycythemia is confirmed, increase phlebotomy frequency to every 7 to 10 days and consider adding a second agent such as chlorambucil or busulfan, though these drugs require specialist consultation.

Rapid PCV Rebound After Phlebotomy

Some dogs with primary polycythemia show rapid PCV rebound within 48 to 72 hours after phlebotomy. This pattern suggests highly active erythroid proliferation. Increase the volume of blood removed in subsequent phlebotomy sessions by 2 to 5 mL per kilogram, provided the dog tolerates the procedure. Consider initiating hydroxyurea at a higher starting dose, such as 20 mg per kilogram per day, and monitor PCV more frequently, every 3 to 4 days, until the rebound slows.

Hydroxyurea-Induced Myelosuppression

Myelosuppression is the most common dose-limiting toxicity of hydroxyurea. If the platelet count drops below 150,000 per microliter or the white blood cell count drops below 4,000 per microliter, hold the drug for 7 to 14 days. Repeat the complete blood count after the drug holiday. Once counts recover, resume hydroxyurea at 50% to 75% of the previous dose. If myelosuppression recurs at the reduced dose, consider switching to an every-third-day dosing schedule or using a lower dose combined with more frequent phlebotomy. Severe or persistent myelosuppression warrants referral to a veterinary internal medicine specialist.

Poor Owner Compliance with Medication and Monitoring

Long-term management of polycythemia requires owner commitment to daily medication administration, regular veterinary visits, and phlebotomy sessions. Educate owners about the chronic nature of the disease and the consequences of treatment interruption. Provide a written treatment schedule and a log for recording medication administration and any observed clinical signs. Schedule recheck appointments before the owner leaves the clinic to reduce missed visits. If compliance remains poor, consider using a longer-acting formulation or simplifying the dosing schedule to every other day.

Comparison of Phlebotomy-Only Versus Combined Phlebotomy and Hydroxyurea

Practical Implementation Steps for Dose Titration

Step 1: Establish Baseline

Measure PCV, complete blood count, serum erythropoietin, and arterial blood gas. Perform imaging studies to classify polycythemia. Record baseline white blood cell count and platelet count.

Step 2: Perform Initial Phlebotomy

If PCV exceeds 60% or clinical signs are present, perform phlebotomy at 15 mL per kilogram. Replace volume with isotonic crystalloid fluids. Measure PCV after the procedure.

Step 3: Repeat Phlebotomy as Needed

Monitor PCV every 24 to 72 hours. Repeat phlebotomy until PCV reaches 45% to 50%. Record the number of sessions required and the total volume removed.

Step 4: Initiate Hydroxyurea

Once PCV is in target range, start hydroxyurea at 15 to 20 mg per kilogram once daily for 7 to 14 days. Reduce to every-other-day dosing for maintenance.

Step 5: Monitor and Adjust

Check PCV and complete blood count weekly for the first month. Adjust hydroxyurea dose based on PCV response and blood cell counts. Once stable, monitor monthly.

Step 6: Long-Term Maintenance

Continue monthly monitoring. Adjust phlebotomy frequency and hydroxyurea dose as needed to maintain PCV between 45% and 50%. Record all treatments and results in the standardized log.

Common Failure Patterns in Dose Titration

Starting Hydroxyurea Too Early

Initiating hydroxyurea before reducing PCV with phlebotomy delays the therapeutic effect and prolongs the period of hyperviscosity. Always perform initial phlebotomy to bring PCV into target range before starting hydroxyurea.

Insufficient Dose Adjustment

Failing to increase the hydroxyurea dose when PCV remains above target leads to persistent hyperviscosity. Increase the dose by 5 to 10 mg per kilogram per day if PCV does not decrease within two weeks.

Overly Aggressive Dose Escalation

Increasing the hydroxyurea dose too rapidly or to too high a level causes myelosuppression. Never exceed 30 mg per kilogram per day without specialist consultation. Monitor blood counts before each dose adjustment.

Ignoring Clinical Signs

Relying solely on PCV without considering clinical signs can lead to undertreatment or overtreatment. A dog with PCV of 52% but showing neurologic signs may require more aggressive therapy than a dog with PCV of 58% that is asymptomatic.

Discontinuing Phlebotomy Too Soon

Some dogs require ongoing phlebotomy even after hydroxyurea therapy is established. Continue phlebotomy until PCV stabilizes in target range for at least four consecutive weeks without phlebotomy.

Welfare and Safety Context

Proper dose titration of phlebotomy and hydroxyurea directly impacts patient welfare. Overly aggressive phlebotomy causes hypovolemia, weakness, and collapse. Inadequate phlebotomy leaves the dog at risk for thromboembolism, stroke, and blindness. Hydroxyurea overdose causes severe myelosuppression leading to infection risk and bleeding tendencies. Underdosing delays PCV control and prolongs hyperviscosity. The World Organisation for Animal Health emphasizes the importance of evidence-based treatment protocols to maintain animal health and welfare (World Organisation for Animal Health, Animal Health and Welfare, https://www.woah.org/en/what-we-do/animal-health-and-welfare).

Handle hydroxyurea with gloves and avoid exposure to pregnant women. Advise owners to wear gloves when administering the medication and to wash hands thoroughly after handling. Store hydroxyurea in a childproof container away from pets and children.

Limitations and Professional Escalation Criteria

The dose titration framework is based on published case reports and clinical experience. Individual dogs may respond differently to phlebotomy and hydroxyurea. The framework does not replace clinical judgment. Refer to a veterinary internal medicine specialist in the following situations:

• PCV remains above 55% after four weeks of hydroxyurea at 30 mg per kilogram per day
• Severe myelosuppression occurs with platelet count below 100,000 per microliter or white blood cell count below 2,500 per microliter
• The dog develops recurrent thromboembolic events despite adequate PCV control
• The dog shows progressive neurologic signs or blindness
• The diagnosis between primary and secondary polycythemia remains unclear after initial workup
• The owner cannot manage the treatment regimen and requires specialist support

Emergency referral is indicated for acute neurologic signs, sudden blindness, or evidence of thromboembolism such as acute pain, limb ischemia, or respiratory distress.

Frequently Asked Questions

What is the difference between relative and absolute polycythemia in dogs?

Relative polycythemia is caused by decreased plasma volume from dehydration or hemoconcentration, while absolute polycythemia represents a true increase in red blood cell mass. Relative polycythemia resolves with fluid therapy, whereas absolute polycythemia requires further investigation to determine if it is primary or secondary.

How do I differentiate primary from secondary polycythemia in dogs?

The key differentiating test is serum erythropoietin concentration. Primary polycythemia (polycythemia vera) shows low or inappropriately normal erythropoietin levels. Secondary polycythemia shows elevated erythropoietin. Arterial blood gas and imaging studies help identify underlying causes of secondary polycythemia.

What PCV level requires treatment in dogs with polycythemia?

Treatment is indicated when PCV exceeds 60% or when clinical signs of hyperviscosity are present. The target PCV after treatment is typically 45-50%. Individualize treatment based on the dog's clinical status and underlying condition.

How often should phlebotomy be performed in dogs with polycythemia vera?

Phlebotomy frequency depends on the rate of PCV increase. Initially, phlebotomy may be needed every 24-72 hours until PCV reaches target. Once hydroxyurea takes effect, phlebotomy frequency decreases, often to every 2-4 weeks or longer.

What are the side effects of hydroxyurea in dogs?

The primary side effect is myelosuppression, particularly thrombocytopenia and leukopenia. Gastrointestinal signs such as vomiting or diarrhea may occur. Long-term use requires monitoring of liver and kidney function. Handle hydroxyurea with gloves due to its chemotherapeutic properties.

Can polycythemia in dogs be cured?

Primary polycythemia (polycythemia vera) is a chronic myeloproliferative disorder that requires lifelong management. Secondary polycythemia may be curable if the underlying cause can be treated, such as surgical removal of a renal tumor or correction of a congenital heart defect.

What is the prognosis for dogs with polycythemia vera?

With appropriate management including phlebotomy and hydroxyurea, many dogs with polycythemia vera have a good quality of life for months to years. Prognosis depends on response to treatment, development of complications such as thromboembolism, and progression of the underlying myeloproliferative disease.

When should I refer a dog with polycythemia to a specialist?

Refer to a veterinary internal medicine specialist if differentiation between primary and secondary polycythemia is unclear, if the dog does not respond to standard treatment, if renal neoplasia is suspected, or if complex cardiac or pulmonary disease is present. Emergency referral is indicated for acute neurologic signs or suspected thromboembolism.

Related Veterinary Guides

• Dog
• Dog Shedding Management
• How To Skin A Dog
• Arthritis In Dogs Symptoms And Diagnosis
• Canine Hyperadrenocorticism Cushings Diagnostic Management

References and Further Reading

• www.merckvetmanual.com
• www.aaha.org
• www.acvim.org
• Merck Veterinary Manual. Merck Veterinary Manual.
• Animal Health and Welfare. World Organisation for Animal Health.
• Polycythemia vera in a dog.. Journal of the American Veterinary Medical Association, 1969.
• Polycythemia vera in dogs.. Journal of the American Veterinary Medical Association, 1974.
• Polycythemia vera in a dog presenting with uveitis.. Journal of the American Animal Hospital Association, 2003.
• Polycythaemia vera in a dog.. The Veterinary record, 1987.
• Diagnosis and Treatment of Primary Erythrocytosis in a Dog: A Case Report.. Topics in companion animal medicine, 2015.
• Polycythaemia vera in a dog.. Journal of the South African Veterinary Association, 1990.
• A case of primary polycythaemia in a dog. Point Veterinaire, 2009.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.